%0 Journal Article
%T Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
%A Chao EC
%J Core Evidence
%D 2012
%I 
%R http://dx.doi.org/10.2147/CE.S16359
%X pagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes Review (3209) Total Article Views Authors: Chao EC Published Date June 2012 Volume 2012:7 Pages 21 - 28 DOI: http://dx.doi.org/10.2147/CE.S16359 Received: 13 March 2012 Accepted: 11 April 2012 Published: 01 June 2012 Edward C Chao University of California, San Diego and VA San Diego Healthcare System, San Diego, CA, USA Abstract: Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the urine (glucosuria) has transformed what was once solely regarded as an adverse facet of diabetes into a potential novel therapeutic strategy. Glucosuria leads to weight loss, due to a reduction in calories, which is thought to rehabilitate insulin sensitivity, at least partially. By acting independently of insulin action or secretion, dapagliflozin appears to avert or minimize two key barriers to optimal glycemic control: hypoglycemia and weight gain. From the clinical studies conducted thus far in patients with type 2 diabetes, dapagliflozin significantly decreases HbA1c (by ~0.5%¨C1%, from a baseline of 8%¨C9%), as well as body weight (~2¨C3 kg), without increased risk of hypoglycemia. Dapagliflozin thus represents a paradigm shift in the treatment of diabetes. While long-term data on safety and efficacy are forthcoming, the results published to date suggest that this agent has the potential to be another option in the treatment of diabetes treatments. This article examines the evidence currently available on the efficacy and safety of dapagliflozin.
%K dapagliflozin
%K SGLT2 inhibitors
%K type 2 diabetes mellitus
%K kidney
%U https://www.dovepress.com/dapagliflozin-an-evidence-based-review-of-its-potential-in-the-treatme-peer-reviewed-article-CE